EuroscreenFast
EuroscreenFast is a Belgian Contract Research Organization providing GPCR screening assay services, custom assay development, and orphan receptor deorphanization to pharmaceutical, biotechnology, academic, and consumer products clients worldwide.
- Company typePrivate
- Founded1994
- HeadquartersGosselies, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What EuroscreenFast does
EuroscreenFast is a Belgium-based Contract Research Organization (CRO) that provides G-Protein Coupled Receptor (GPCR) screening assay services to pharmaceutical, biotechnology, academic, cosmetic, and nutraceutical clients. It operates as a business unit of Epics Therapeutics S.A., headquartered in Gosselies, Belgium, and traces its lineage to a 1994 spin-off from the Université Libre de Bruxelles (ULB). The unit was carved out of Ogeda S.A. (formerly Euroscreen S.A.) via a Business Transfer Agreement to Epics Therapeutics in December 2018.
The company's core offering is a catalog of more than 1,000 functional and radioligand binding assays covering 530+ GPCR targets, executed across multiple readouts including Aequorin (calcium flux), cAMP HTRF, IPOne, GTPγS radiometric, ERK1/2 phosphorylation, TagLite-based receptor internalization, and radioligand/fluorescent binding. Beyond catalog screening, EuroscreenFast delivers custom assay development, stable cell line development using bicistronic expression vectors, and a differentiated GPCR Deorphanization Platform that combines a library of cellular tools with a unique collection of natural tissue extracts and 30+ years of accumulated expertise. The platform has produced 17 successful receptor-ligand pair identifications, including notable collaborations with Novartis on EBI2 and GPR15. Profiling is delivered through preset panels (57 GPCR Diversity, 76-target Orphan GPCR, 44-target Safety, disease-focused therapeutic area panels, and receptor family panels).
EuroscreenFast generates revenue on a fee-for-service, quote-based CRO model with standard 15-business-day turnaround and a 5-business-day Fast TAT option, marketed via direct enterprise sales, website quote requests, scientific conference attendance, and a 2024 channel partnership with BioPharma Consultants for Indian market expansion. A 2026 commercial agreement with AsedaSciences integrates its GPCR assays into a toxicity risk assessment workflow, broadening the addressable market into chemical and pharmaceutical safety profiling. The customer base exceeds 300 organizations worldwide, with named engagements including Novartis, EMD Serono (Merck KGaA), and the National Multiple Sclerosis Society. The unit is privately held, with no public revenue disclosure and a reported headcount in the 1-10 range.
EuroscreenFast firmographics
Firmographics- Name
- EuroscreenFast
- Legal name
- Epics Therapeutics S.A.
- Website
- https://euroscreenfast.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EuroscreenFast is a Belgian Contract Research Organization providing GPCR screening assay services, custom assay development, and orphan receptor deorphanization to pharmaceutical, biotechnology, academic, and consumer products clients worldwide.
- Ownership category
- akta.pro rank
EuroscreenFast industry classification
Industry- Product category
- Contract Research Organization (Drug Discovery Services)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where EuroscreenFast is headquartered
LocationHeadquarters
- HQ city
- Gosselies
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
EuroscreenFast business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- GPCR Screening Services: Fee-for-service CRO model providing GPCR screening assays to pharmaceutical, biotech, cosmetic/nutraceutical companies and academic institutions. Services include high throughput screening, molecular pharmacology and profiling.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based custom pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
EuroscreenFast product offering
Product offeringCore offering
EuroscreenFast is a Contract Research Organization (CRO) providing fee-for-service GPCR (G-Protein Coupled Receptor) screening and assay development for pharmaceutical, biotech, cosmetic/nutraceutical and academic customers. Its core deliverable is laboratory execution of GPCR assays drawn from a validated catalogue of 1,000+ functional and radioligand binding assays covering 530+ GPCR targets, using multiple readouts (Aequorin, cAMP HTRF, IPOne, GTPγS, ERK1/2, TagLite, radioligand binding). Complementary offerings include custom cell line development, profiling panels, and a proprietary GPCR deorphanization platform that has identified natural ligands in 17 successful programs.
Product overview
EuroscreenFast is a CRO (Contract Research Organization) specializing in GPCR screening assay services with over 30 years of expertise. The company operates as a business unit of Epics Therapeutics SA. The core offering consists of the GPCR Screening Assay Catalogue with more than 530 targets and 1,000+ assays, complemented by Assay Development and Cell Line Development services for custom needs. Profiling is offered through preset panels including the 57 GPCR Diversity Panel, Orphan GPCR Panel (76 receptors), Safety Panel (44 targets), and disease-focused Therapeutic Area Panels (CNS, Metabolic, Inflammation, Sensory Pain) as well as Receptor Family Panels. The GPCR Deorphanization Platform enables identification of natural ligands for orphan receptors, with a track record of 17 successful programs. Specialized assays include kinetics, chemotaxis, cytokine release, and enzymatic testing. Services utilize multiple assay readouts including Aequorin (calcium flux), cAMP, IPOne, GTPγS, ERK1/2, receptor internalization, and radioligand binding.
Differentiator
Problem solved
Functional benefit
Products and services
- GPCR Screening Assay Catalogue Comprehensive catalogue of over 530 GPCR targets represented by more than 1,000 functional and radioligand binding assays for high throughput screening, molecular pharmacology and profiling, offered as fee-for-service CRO execution for pharmaceutical, biotech, cosmetic/nutraceutical and academic customers.
- Assay Development Services Custom development of recombinant cell lines expressing the customer's target receptors and validation with functional or binding assays of choice, delivered as a customized CRO project.
- Cell Line Development Custom-engineered stable cell lines expressing targets of choice using high-copy bicistronic expression vectors, with selection of stable pool or clonal selection, offered as a stand-alone CRO service.
- GPCR Deorphanization Platform Proprietary platform combining cellular tools, a natural tissue extracts library and 20+ years of expertise for identifying natural ligands of orphan GPCRs, with a track record of 17 successful deorphanization programs, offered as a CRO collaboration service.
- 57 GPCR Diversity Panel Off-the-shelf profiling panel testing compounds against 57 GPCR targets representing main receptor families for selectivity and off-target effects assessment.
- Orphan GPCR Panel Panel of 76 orphan receptors tested using the most appropriate readouts including cAMP, Aequorin and IPOne based on receptor characteristics.
- Therapeutic Area Panels Disease-focused profiling panels including CNS (36 targets), Metabolic (54 targets), Inflammation (56 targets), and Sensory Pain (41 targets) panels.
- Receptor Family Panels Family-based selectivity panels including Metabotropic Glutamate (8 targets), Muscarinic (5 targets), Serotonin (14 subtypes), and Chemokine (21 receptors) panels.
- Safety Panel Off-the-shelf panel of 44 GPCR, ion channel, transporter and enzyme targets for assessing potential safety issues in drug development.
- Specialized Assays Advanced assays including kon/koff kinetics, cell migration (chemotaxis), cytokine release, glucose-stimulated insulin secretion (GSIS), and enzymatic assays, offered as fee-for-service CRO execution.
Quantifiable outcome
- Over 1,000 functional and radioligand binding assays available for 530+ GPCR targets
- +3 more outcomes
Companies that use EuroscreenFast
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
EuroscreenFast technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EuroscreenFast partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- AsedaSciencescoreCommercial sales and marketing agreement to integrate EuroscreenFast's GPCR screening capabilities into AsedaSciences' 3RnD toxicity risk assessment platform. Partnership provides customers access to over 1,000 functional assays covering more than 560 GPCR and related targets, strengthening mechanistic measurement of receptor-mediated toxicity risk in chemical and pharmaceutical development.
- BioPharma ConsultantscoreStrategic partnership with specialist Indian provider of life science technology solutions based in Pune. BioPharma Consultants serves as local agent to expand EuroscreenFast's presence in Indian market and broader sub-continent region. Partnership aimed at bringing innovative GPCR expertise to novel drug developers and generics manufacturers in India.
Scale indicators5 records
Recent moves10 records
Expansion highlights4 records
EuroscreenFast competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: European-headquartered global bioanalytical testing and CRO conglomerate with pharmacology and cell-based assay services. Acts as parent of the closest direct competitor and competes broadly for outsourced discovery contracts.
- Charles River Laboratories: Global preclinical CRO offering safety pharmacology, discovery, and DMPK services including receptor pharmacology panels. Significant scale advantage over EuroscreenFast but overlaps as a vendor for enterprise pharma GPCR work.
- WuXi AppTec: China-based global CRO/CDMO with comprehensive preclinical and discovery services including pharmacology assay offerings. Provides scale and Asia-region reach that EuroscreenFast lacks.
Direct peers
- Innoprot: Spanish cell-line and assay-development CRO providing GPCR-expressing cell lines, functional assays, and custom drug discovery services. Overlaps with EuroscreenFast on cell line development and recombinant assay production.
- Eurofins Discovery (formerly DiscoverX): Eurofins' discovery services arm includes the legacy DiscoverX/DiscoveRx GPCR screening platform. The most direct head-to-head competitor to EuroscreenFast, offering comparable GPCR functional and binding assays, deorphanization services, and a global commercial footprint.
- Reaction Biology Corporation: US-based preclinical CRO specializing in GPCR, kinase, and other pharmacology assay services. Closely matches EuroscreenFast's CRO model of fee-for-service screening, profiling, and custom assay development for pharma/biotech sponsors.
- QPS Holdings: Mid-sized preclinical CRO with broad discovery and DMPK services including cell-based and receptor pharmacology offerings. Comparable to EuroscreenFast as a fee-for-service discovery CRO serving large pharma.
- Multispan Inc. US-based CRO focused exclusively on GPCR cell lines, stable clones, and functional assays for high-throughput screening. Closely matched specialty CRO with comparable recurring-customers profile in pharma/biotech.
- NMI TT Pharmaservices: German-based CRO offering GPCR profiling, cell-based assays, and safety pharmacology for drug discovery. Comparable niche specialist operating in the same European preclinical CRO market with similar target-class focus.
- Cyprotex (Eurofins): Preclinical ADME-Tox and pharmacology CRO (now owned by Eurofins) offering mechanistic safety and cell-based pharmacology services. Comparable niche-specialist positioning with overlapping customer segments in safety profiling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
EuroscreenFast social profiles
Digital presenceEuroscreenFast financial estimates
Financial estimateRevenue estimate
Valuation estimate
EuroscreenFast leadership team
Management profileNumber of profiles
Profiles1 record
EuroscreenFast funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EuroscreenFast M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EuroscreenFast
What does EuroscreenFast do?
EuroscreenFast is a Contract Research Organization (CRO) providing fee-for-service GPCR (G-Protein Coupled Receptor) screening and assay development for pharmaceutical, biotech, cosmetic/nutraceutical and academic customers. Its core deliverable is laboratory execution of GPCR assays drawn from a validated catalogue of 1,000+ functional and radioligand binding assays covering 530+ GPCR targets, using multiple readouts (Aequorin, cAMP HTRF, IPOne, GTPγS, ERK1/2, TagLite, radioligand binding). Complementary offerings include custom cell line development, profiling panels, and a proprietary GPCR deorphanization platform that has identified natural ligands in 17 successful programs.
Is EuroscreenFast a public or private company?
EuroscreenFast is a private company. It is classified as corporate owned and is currently operating.
When was EuroscreenFast founded?
EuroscreenFast was founded in 1994. It employs 1 to 10 people.
Where is EuroscreenFast based?
EuroscreenFast is headquartered in Gosselies, Belgium, in the Europe region.
How does EuroscreenFast make money?
One revenue line is on record: GPCR Screening Services.
Who are EuroscreenFast's main competitors?
Broad incumbents on record are Eurofins Scientific, Charles River Laboratories and WuXi AppTec. Direct peers are Innoprot, Eurofins Discovery (formerly DiscoverX), Reaction Biology Corporation, QPS Holdings, Multispan Inc., NMI TT Pharmaservices and Cyprotex (Eurofins).
Does EuroscreenFast have an API?
No public API is recorded for EuroscreenFast.
What industry is EuroscreenFast in?
EuroscreenFast's product category is Contract Research Organization (Drug Discovery Services). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 5417 and its SIC code is 8071.